Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

debbiekatz May. 13 at 4:15 AM

$SNGX .31 - finally bottomed out at .28

0 · Reply

Evissamwohs May. 13 at 2:05 AM

$SNGX Where Are the people here?

0 · Reply

mike537 May. 8 at 7:42 PM

$SNGX sold at a massive loss. This garbage is going to zero.

0 · Reply

GreedyGopher May. 8 at 3:12 PM

$SNGX 🤣🤣🤣🤣

1 · Reply

nightstocker15 May. 8 at 1:10 PM

$SNGX year of cash on the books and strategic review for potential merger/acquisition. In the load zone 💪

0 · Reply

focafoca99 May. 8 at 11:54 AM

$SNGX notes disappointing FLASH2 trial outcome and reports Q1 2026 net loss of $2.8 million.

0 · Reply

TwongStocks May. 8 at 11:35 AM

$SNGX Soligenix Announces Recent Updates and First Quarter 2026 Financial Results https://www.prnewswire.com/news-releases/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results-302766364.html • Approx $6M in cash at end of March, runway into Q2 2027 • Regarding FLASH study --> "If there is any clarity gained from further analysis of the dataset, especially with respect to specific subsets of patients that may benefit from HyBryte™ therapy, then we intend to communicate our findings and explore follow-up discussions with the European Medicines Agency (EMA) and the Food and Drug Administration (FDA)." • Next steps --> "we will evaluate all strategic options moving forward, including but not limited to merger and acquisition opportunities, and the potential of advancing SGX945 (dusquetide) for the treatment of Behçet's Disease..."

0 · Reply

GreedyGopher May. 8 at 1:43 AM

$SNGX Why would anyone buy this turd? You may think you're scoring a bargain buying a pile of shares st $.25 pps ..........until they do another 1 for 15 reverse split folowed by a dilution of millions of shares. .....like they have done twice in the last 5 years.......save the trouble and just put your cash in an envelope and mail it to Schaber. . .thank you come again

0 · Reply

profitkiller May. 6 at 8:00 PM

$SNGX bought more at .33

0 · Reply

debbiekatz May. 4 at 3:04 PM

$SNGX at .35 to .36. last posted at .34 to .35

0 · Reply

Soligenix reports Q1 EPS (28c) vs. (97c) last year

May 8, 2026, 7:30 AM EDT - 5 days ago

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

2026-05-04T11:16:01.000Z - 9 days ago

Soligenix price target lowered to $1.50 from $10 at Alliance Global

2026-04-28T12:08:02.000Z - 15 days ago

Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma

Apr 28, 2026, 7:30 AM EDT - 15 days ago

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

2026-04-02T12:03:59.000Z - 5 weeks ago

Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

Apr 2, 2026, 7:30 AM EDT - 5 weeks ago

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Mar 31, 2026, 7:30 AM EDT - 6 weeks ago

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

2026-03-26T11:36:24.000Z - 6 weeks ago

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

Mar 26, 2026, 7:30 AM EDT - 6 weeks ago

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Mar 23, 2026, 7:30 AM EDT - 7 weeks ago

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Mar 19, 2026, 8:00 AM EDT - 7 weeks ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

2026-03-19T11:36:43.000Z - 7 weeks ago

Soligenix announces HyBryte clinical summary published

Mar 19, 2026, 7:30 AM EDT - 7 weeks ago

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

2026-03-10T11:42:32.000Z - 2 months ago

Soligenix says SGX945 granted PIM designation in UK by MHRA

Mar 10, 2026, 7:30 AM EDT - 2 months ago

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

2026-02-26T13:00:59.000Z - 2 months ago

Soligenix receives positive opinion from EMA for OOD request for dusquetide

Feb 26, 2026, 7:30 AM EST - 2 months ago

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Feb 24, 2026, 7:30 AM EST - 2 months ago

Soligenix to Present at BIO Investment & Growth Summit

Feb 12, 2026, 7:30 AM EST - 3 months ago

Soligenix Details Recent Progress and Upcoming Milestones

2025-12-18T12:41:21.000Z - 5 months ago

Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)

Dec 18, 2025, 7:30 AM EST - 5 months ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

2025-12-17T12:36:34.000Z - 5 months ago

Soligenix announces results from Phase 2a trial of SGX302

Dec 17, 2025, 7:30 AM EST - 5 months ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 3, 2025, 8:30 AM EST - 5 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

2025-11-19T12:35:43.000Z - 6 months ago

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

Nov 19, 2025, 7:30 AM EST - 6 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 7, 2025, 7:30 AM EST - 6 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Oct 14, 2025, 7:30 AM EDT - 7 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

2025-10-07T11:35:32.000Z - 7 months ago

Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial

Oct 7, 2025, 7:30 AM EDT - 7 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

2025-09-30T11:35:29.000Z - 8 months ago

Soligenix expands European Medical Advisory Board for CTCL

Sep 30, 2025, 7:30 AM EDT - 8 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 29, 2025, 4:05 PM EDT - 8 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 8 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 23, 2025, 7:30 AM EDT - 8 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

2025-09-19T21:05:11.000Z - 8 months ago

Soligenix files to sell 2.91M shares of common stock, 2.91M warrants

2025-09-04T11:35:46.000Z - 8 months ago

Soligenix’s ThermoVax platform shows efficacy in vaccine stability

Sep 4, 2025, 7:30 AM EDT - 8 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 2, 2025, 7:30 AM EDT - 9 months ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-18T11:35:27.000Z - 9 months ago

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

Aug 18, 2025, 7:30 AM EDT - 9 months ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

2025-08-13T22:00:32.000Z - 9 months ago

Soligenix receives FDA orphan designation for dusquetide

Aug 8, 2025, 8:30 AM EDT - 9 months ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

2025-08-01T01:30:00.000Z - 10 months ago

Why Is Soligenix Stock (SNGX) Up 50% Today?

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 1 year ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 7, 2024, 7:30 AM EDT - 1 year ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

debbiekatz May. 13 at 4:15 AM

$SNGX .31 - finally bottomed out at .28

0 · Reply

Evissamwohs May. 13 at 2:05 AM

$SNGX Where Are the people here?

0 · Reply

mike537 May. 8 at 7:42 PM

$SNGX sold at a massive loss. This garbage is going to zero.

0 · Reply

GreedyGopher May. 8 at 3:12 PM

$SNGX 🤣🤣🤣🤣

1 · Reply

nightstocker15 May. 8 at 1:10 PM

$SNGX year of cash on the books and strategic review for potential merger/acquisition. In the load zone 💪

0 · Reply

focafoca99 May. 8 at 11:54 AM

$SNGX notes disappointing FLASH2 trial outcome and reports Q1 2026 net loss of $2.8 million.

0 · Reply

TwongStocks May. 8 at 11:35 AM

0 · Reply

GreedyGopher May. 8 at 1:43 AM

0 · Reply

profitkiller May. 6 at 8:00 PM

$SNGX bought more at .33

0 · Reply

debbiekatz May. 4 at 3:04 PM

$SNGX at .35 to .36. last posted at .34 to .35

0 · Reply

PaulLaurent May. 2 at 7:05 PM

📉🔻 Top Losers 🔻📉Last Week $AREB $CHSN $SNGX $HUBC $SDOT

0 · Reply

Vladxccc May. 1 at 3:27 PM

$SNGX 5000 shares at .34 , f**k it why not

1 · Reply

GreedyGopher May. 1 at 1:27 PM

$SNGX In the last 5 years, this company which has never brought ANYTHING to market, is down 99.91% The CEO is still highly compensated although all of his investors have lost everything.......time to pull the plug on thus turd of a company.

0 · Reply

Sngxscam May. 1 at 10:56 AM

$SNGX Decieve delay dilute.

0 · Reply

debbiekatz May. 1 at 6:05 AM

$SNGX .34-.35 worth a shot

0 · Reply

Vote4Pedro2 May. 1 at 12:36 AM

$SNGX

0 · Reply

mrjamesgriffith Apr. 30 at 7:42 PM

$SNGX $AREB time to buy it hold it and double it. Opportunity favors those who are open to risk and volatility. Money comes in and leaves like waves in the ocean 🌊 high tide is coming don't sell because you can't see the incoming wave. Hold and relax.

0 · Reply